Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 15INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 12Thoracic 8Plasma cell 7Dermatologic 5Tumor-Agnostic 3Gastrointestinal 2Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Vorinostat × Gastrointestinal × Clear all
NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

NCT00126451 2017-04-10

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 2 Terminated
16 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡